Drug intelligence / Profile preview

SPH-101

Development stage: Preclinical
Lead developer: Sapphire Therapeutics
Administration: Oral

Overview

SPH-101 is an orally administered drug candidate being developed by Sapphire Therapeutics for the treatment of ulcerative colitis. It utilizes a non-immunosuppressive approach to treating inflammatory bowel disease (IBD) by targeting a novel, undisclosed receptor that modulates NFkB and interleukin-22 (IL-22) related pathways. This mechanism is intended to promote mucosal healing and restore epithelial barrier function without the systemic immune suppression associated with many current IBD therapies. As of early 2024, SPH-101 is in the lead identification/preclinical stage of development.

Beyond the preview

Go deeper on SPH-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPH-101.

Explore the full profile